Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus ZJCH-ALL-R1 for relapsed childhood acute lymphoblastic leukemia
ChiCTR2100045759Phase 3Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Jun 2021
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bortezomib in acute lymphoblastic leukemia (ALL), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Peripheral blood not restored to remission, Complete response rate and 3 more. Started Jun 2021; status: recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2100045759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045759.